Optimal adaptive sequential designs for crossover bioequivalence studies |
| |
| Authors: | Jialin Xu Charles Audet Charles E DiLiberti Walter W Hauck Timothy H Montague Alan F Parr Diane Potvin Donald J Schuirmann |
| |
| Institution: | 1. Merck & Co., Inc.,, Upper Gwynedd, PA,, USA;2. GERAD and Ecole Polytechnique de Montreal,, Montreal, QC,, Canada;3. Montclair Bioequivalence Services, LLC, NJ, USA;4. Sycamore Consulting LLC, New Hope, PA,, USA;5. GlaxoSmithKline, Inc., King of Prussia, PA,, USA;6. GlaxoSmithKline, Inc., Research Triangle Park, Durham, NC, USA;7. Excelsus Statistics Inc., Montreal, QC, Canada;8. Center for Drug Evaluation and Research, US Food and Drug Administration, MD, USA |
| |
| Abstract: | In prior works, this group demonstrated the feasibility of valid adaptive sequential designs for crossover bioequivalence studies. In this paper, we extend the prior work to optimize adaptive sequential designs over a range of geometric mean test/reference ratios (GMRs) of 70–143% within each of two ranges of intra‐subject coefficient of variation (10–30% and 30–55%). These designs also introduce a futility decision for stopping the study after the first stage if there is sufficiently low likelihood of meeting bioequivalence criteria if the second stage were completed, as well as an upper limit on total study size. The optimized designs exhibited substantially improved performance characteristics over our previous adaptive sequential designs. Even though the optimized designs avoided undue inflation of type I error and maintained power at  80%, their average sample sizes were similar to or less than those of conventional single stage designs. Copyright © 2015 John Wiley & Sons, Ltd. |
| |
| Keywords: | sequential design sample size re‐estimation adaptive design bioequivalence |
|
|
